# MitoCheck® Complex I Activity Assay Kit

Item No. 700930





Customer Service 800.364,9897 \* Technical Support 888.526.5351 www.caymanchem.com

#### TABLE OF CONTENTS

GENERAL INFORMATION 3 Materials Supplied

4 Precautions

4 If You Have Problems

4 Storage and Stability

4 Materials Needed but Not Supplied

INTRODUCTION 5 Background

6 About This Assay

PRE-ASSAY PREPARATION 7 Reagent Preparation

ASSAY PROTOCOL 9 Performing the Assay

ANALYSIS 10 Calculations

11 Performance Characteristics

**RESOURCES** 12 Troubleshooting

13 References

13 Related Products

14 Warranty and Limitation of Remedy

15 Plate Template

16 Notes

#### **GENERAL INFORMATION**

# **Materials Supplied**

Kit will arrive packaged as a -80°C kit. For best results, remove components and store as stated below.

Item Number	ltem	Quantity/Size	Storage
700931	Mitochondrial Complex I Activity Assay Buffer	2 vials/10 ml	-20°C
700018	Ubiquinone Assay Reagent	1 vial/100 μl	-80°C
700932	NADH Assay Reagent	1 vial/500 μg	-20°C
700019	Bovine Heart Mitochondria Assay Reagent	1 vial/100 μl	-80°C
700933	Fatty Acid Free - BSA Assay Reagent	1 vial/250 μl	-20°C
700020	Half Volume 96-Well Clear Plate	1 plate	Room temperature

If any of the items listed above are damaged or missing, please contact our Customer Service department at (800) 364-9897 or (734) 971-3335. We cannot accept any returns without prior authorization.



WARNING: This product is for laboratory research use only: not for administration to humans. Not for human or veterinary diagnostic or therapeutic use.

### **Precautions**

Please read these instructions carefully before beginning this assay.

For research use only. Not for human or diagnostic use.

NOTE: It is recommended that gloves be worn at all time when working with isolated mitochondria and mitochondrial inhibitors.

### If You Have Problems

#### **Technical Service Contact Information**

**Phone:** 888-526-5351 (USA and Canada only) or 734-975-3888

Fax: 734-971-3641

Email: techserv@caymanchem.com
Hours: M-F 8:00 AM to 5:30 PM EST

In order for our staff to assist you quickly and efficiently, please be ready to supply the lot number of the kit (found on the outside of the box).

# Storage and Stability

This kit will perform as specified if stored as directed in the **Materials Supplied** section on page 3 and used before the expiration date indicated on the outside of the box.

# **Materials Needed But Not Supplied**

- 1. A plate reader capable of measuring absorbance a 340 nm at 30 second intervals
- 2. Adjustable and multichannel pipettes
- 3. A source of pure water; glass distilled water or HPLC-grade water is acceptable
- 4. Mitochondrial Inhibitors Rotenone, Potassium Cyanide, or Antimycin A
- 5. 0.1 M NaOH

#### INTRODUCTION

# **Background**

Complex I (NADH oxidase/Co-enzyme Q reductase) is one of the major sites of electron entry into the mitochondrial electron transport chain (ETC). Complex I catalyzes the 2 electron oxidation of NADH followed by the reduction of ubiquinone (Q) to form ubiquinol (QH<sub>2</sub>), and ultimately the reduction of the terminal electron acceptor, O<sub>2</sub>. During the passage of electrons from NADH to Q, the translocation of four protons (H<sup>+</sup>) from the mitochondrial matrix to the intermembrane space occurs, contributing to the chemiosmotic proton gradient, which is required for oxidative phosphorylation. Inhibition of complex I results in severe mitochondrial dysfunction and increased production of reactive oxygen species. Long-term inhibition of complex I has been linked to neurological disorders such as Parkinson's disease, Down's syndrome, and Leigh's syndrome, making it a useful indicator for neurological defects resulting from mitochondrial toxicity. This assay is designed so that direct inhibitory effects on complex I can be readily observed. Common inhibitors of complex I activity include rotenone and piericidin.

# **About This Assay**

Cayman's MitoCheck<sup>®</sup> Complex I Activity Assay allows for the activity of complex I to be determined without the need to isolate mitochondria or pre-incubate with antibodies. The rate of NADH oxidation is measured by a decrease in absorbance at 340 nm and is proportional to the activity of complex I. The rate of NADH oxidation by complex I is fully inhibited by the prototypical complex I inhibitor rotenone (1  $\mu$ M) (not supplied). For the use of this kit with other types of tissue mitochondria, please see Cayman's MitoCheck<sup>®</sup> Mitochondrial (Tissue) Isolation Kit (Item No. 701010).




Figure 1. Reaction catalyzed by complex I, as measured in this assay kit.

#### PRE-ASSAY PREPARATION

# **Reagent Preparation**

All assay reagents, unless listed below, are ready to use as supplied.

### 1. Mitochondrial Complex I Activity Assay Buffer - (Item No. 700931)

This buffer is ready to use as supplied. It is important that the buffer is warmed to room temperature prior to use. Additionally, vortex well to be sure that any crystals that may have precipitated have dissolved.

### 2. NADH Assay Reagent - (Item No. 700932)

Each vial contains lyophilized NADH. Dissolve in 155  $\mu$ l of ultra-pure water. The solution is stable on ice for three hours and should be stored at -20°C once reconstituted (use within two weeks).

### 3. Mitochondrial Inhibitors - (Not Supplied)

- 1. Potassium Cyanide (KCN) KCN should be present to inhibit the ETC (complex IV) and prevent the oxidation of Q. It is important that extreme care is taken when preparing and using KCN. Protocol: In a ventilated hood, weigh out 6.5 mg of KCN and dissolve in 1 ml of 0.1 M NaOH to yield a 100 mM stock solution of KCN. Do not use water or any acidic solvents to make up KCN. Store stock solution on ice and make fresh less than three hours prior to running this assay. Use appropriate personal protective equipment (PPE).
- Rotenone (Item No. 13995) to ensure inhibition of complex I, use concentrations
  ≥1 μM. This solution can be made up in DMSO or ethanol. If making up in
  DMSO, avoid freeze/thaws. Use appropriate PPE.
- 3. Antimycin A to ensure inhibition of complex III, use concentrations ≥10 μM. Can be made up in DMSO or ethanol. Use appropriate PPE.

#### **ASSAY PROTOCOL**

#### **Pipetting Hints**

- Use different tips to pipette each reagent.
- Avoid introducing bubbles into the well.
- Do not expose the pipette tip to the reagent(s) already in the well.

#### **General Information**

- The final volume of the assay is 100 μl in all wells.
- It is not necessary to use all the wells on the plate at one time.
- It is recommended that the samples be assayed at least in duplicate (triplicates preferred).
- The assay is performed in the kinetic read mode at 25°C.
- Monitor the absorbance at 340 nm every 30 seconds for 15 minutes.

# **Performing the Assay**

Label two polystyrene tubes as A and B and add the following reagents. *Isolated mitochondria* can settle over time, so make sure contents of each tube are well mixed. Store tubes on ice until ready to use. Volumes indicated below are suitable for 20 reactions (or wells). Customer may scale volumes as needed.

Tube A (1 ml)	Tube B (675 μl)
910 µl of Complex I Activity Assay Buffer	625 μl of Complex I Activity Assay Buffer
20 μl of 100 mM KCN (1 mM) *not supplied*	30 μl of NADH Assay Reagent
50 μl FF-BSA Assay Reagent	20 µl of Ubiquinone Assay Reagent
20 μl Bovine Heart Mitochondria Assay Reagent	

#### **Table 1. Assay preparation**

All assays are carried out at 25°C.

- 1. Add 50 μl of the contents of tube A to each well.
- 2. Add 20 µl of test compound, positive control, or vehicle diluted in Assay Buffer to each well. Allow for pre-incubation if required.
- 3. Add 30  $\mu$ l of the contents of tube B to each well. This should be done quickly as the reaction will start immediately.
- Immediately place plate in plate reader and measure absorbance at 340 nm (30 second intervals for 15 minutes at 25°C).

#### **ANALYSIS**

### **Calculations**

- 1. Plot data as absorbance (y-axis) versus time (x-axis).
- 2. To determine the reaction rate, calculate the slope for the linear portion of the curve.
- Determine % activity relative to the vehicle control using the equation indicated below.
- 4. To determine an  $IC_{50}$  value for each compound, plot the slope as a function of test compound concentration.

### **Performance Characteristics**

The data shown below are an example of data obtained with this kit. Your results will not be identical to these.




Figure 3. A typical concentration response curve for inhibition of complex I activity by rotenone ( $IC_{50} = 131 \text{ nM}$ ). "Veh." represents compound vehicle control.

#### RESOURCES

# **Troubleshooting**

Problem	Possible Causes	Recommended Solutions
Erratic values; dispersion of duplicates/triplicates	A. Poor pipetting/technique     B. Bubble in the well(s)     C. Poor test compound solubility	A. Be careful not to splash the contents of the wells     B. Carefully tap the side of the plate with your finger to remove bubbles     C. Test solubility with assay buffer
No activity was detected in test compound wells	Test compound is a potent inhibitor	Check vehicle controls to be sure complex I is active
Test compound absorbance is above saturating positive control (i.e., rotenone) absorbance	Test compound absorbs at 340 nM	Determine absorbance of compounds in the absence of NADH; subtract this value from all wells containing test compound

### **References**

- 1. Brown, G.C. and Brand, M.D. Proton/electron stoichiometry of mitochondrial complex I estimated from the equilibrium thermodynamic force ratio. *Biochem. J.* **252(2)**, 473-479 (1988).
- 2. Li, N., Ragheb, K., Lawler, G., *et al.* Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. *J. Biol. Chem.* **278(10)**, 8516-8525 (2003).
- 3. Sherer, T.B., Betarbet, R., Testa, C.M., *et al.* Mechanism of toxicity in rotenone models of Parkinson's disease. *J. Neurosci.* **23(34)**, 10756-10764 (2003).
- 4. Papa, S. and De Rasmo, D. Complex I deficiencies in neurological disorders. *Trends Mol. Med.* **19(1)**, 61-69 (2013).
- Janetzky, B., Hauck, S., Youdim, M.B.H., et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci. Lett. 169(1-2), 126-129 (1994).

### **Related Products**

Aconitase Assay Kit - Item No. 705502

Aconitase Fluorometric Assay Kit - Item No. 700600

JC-1 Mitochondrial Membrane Potential Assay Kit - Item No. 10009172

MitoCheck® Citrate Synthase Activity Assay Kit - Item No. 701040

MitoCheck® Complex II Activity Assay Kit - Item No. 700940

MitoCheck® Complex II/III Activity Assay Kit - Item No. 700950

MitoCheck® Complex IV Activity Assay Kit - Item No. 700990

MitoCheck® Complex V Activity Assay Kit - Item No. 701000

MitoCheck® Mitochondrial (Tissue) Isolation Kit - Item No. 701010

Oxygen Consumption Rate Assay Kit (MitoXpress<sup>®</sup>-Xtra HS Method) - Item No. 600800

# **Warranty and Limitation of Remedy**


14

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman **warrants only** to the original customer that the material will meet our specifications at the time of delivery. Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have **any obligation or liability**, whether in tort (including negligence) or in contract, for any direct, incidental or consequential damages, even if Cayman is informed about their possible existence. This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's **exclusive remedy** and Cayman's sole liability hereunder shall be limited to a <u>refund</u> of the purchase price, or at Cayman's option, the <u>replacement</u>, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our Warranty and Limitation of Remedy located on our website and in our catalog.



15

RESOURCES RESOURCES

### **NOTES**

This document is copyrighted. All rights are reserved. This document may not, in whole or part, be copied, photocopied, reproduced, translated, or reduced to any electronic medium or machine-readable form without prior consent, in writing, from Cayman Chemical Company.

©12/21/2015, Cayman Chemical Company, Ann Arbor, MI, All rights reserved. Printed in U.S.A.